Hi, casirivimab and imdevimab is administered together for the treatment of mild to moderate (COVID-19) in adults and pediatric patients above 12 years of age with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
Not for all children with covid 19
Only high risk group It is administered intravenously and has its own set of pros and cons.
Answered2021-05-09 03:38:26
1/1 people found this helpful